Regeneron price target raised to $815 from $810 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $815 from $810 and keeps a Buy rating on the shares. Q2 performance beat investor expectations on strong Dupixent sales and “a good performance from a struggling Eylea franchise,” the analyst says in a post-earnings note. Management made “some interesting comments on the call regarding BD strategy,” adds the analyst, who gets a sense that the company is now open to considering “differentiated later stage opportunities in areas with high unmet medical need” versus a prior focus on early-stage assets.